Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500594 | 0.95 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL6494354 | 0.95 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL6492141 | 0.95 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL6492268 | 0.95 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL6500485 | 0.94 | AGTR1 (0.42) | AGTR1AGTR2 | |
| SCHEMBL6491839 | 0.94 | AGTR1 (0.42) | AGTR1AGTR2 | |
| SCHEMBL6502648 | 0.94 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL6492105 | 0.93 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL6490838 | 0.93 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL6492945 | 0.93 | AGTR1 (0.41) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0073451-B1 | CARBAPENAM COMPOUND AND PROCESSES FOR THE PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-05-13 | — | — | EP | claimed |
| EP-0073451-A2 | Carbapenam compound and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-03-09 | — | — | EP | claimed |
| US-4327093-A | TREATING INFECTIONS DISEASES, ANTIBACTERIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-04-27 | — | — | US | claimed |
| EP-0010313-A1 | 3,7-Disubstituted-2- or -3-cephem-4-carboxylic acid compounds, pharmaceutical compositions containing them and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-30 | — | — | EP | claimed |
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G. D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| US-6630497-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO | 2003-10-07 | — | — | US | disclosed |
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. | 2002-03-28 | — | — | US | disclosed |
| EP-1160243-A1 | PROCESS FOR PRODUCING QUINAZOLINE DERIVATIVE OR SALT THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-4462999-A | CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-31 | — | — | US | disclosed |
| EP-0108977-A2 | Starting compounds for preparing 7-acylamino-3-substituted cephalosporanic acid derivatives and process for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-23 | — | — | EP | disclosed |
| EP-0010667-B1 | CEPHAM COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION THEREOF AND OF KNOWN CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-07-20 | — | — | EP | disclosed |
| EP-0073451-A2 | Carbapenam compound and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-03-09 | — | — | EP | disclosed |
| EP-0071891-A2 | New cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | disclosed |
| US-4363807-A | BACTERICIDES AND USEFUL ANTIBIOTIC INTERMEDIATES | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1982-12-14 | — | — | US | disclosed |
| EP-0029557-A2 | 7-Acylamino-3-substituted cephalosporanic acid derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-03 | — | — | EP | disclosed |
| EP-0010667-A1 | Cepham compounds, pharmaceutical compositions containing them and processes for the preparation thereof and of known cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | AGTR1 227/4885AGTR2 264/4885 |
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | AGTR1 10/4885AGTR2 17/4885 |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | AGTR1 11/4885AGTR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.